Purchases are not available yet. You can browse the site and sign in.
Does Microdosing Work? What the Research Really Says · Microdosing College
Science
Does microdosing work? What the research actually shows
By Microdosing College Editorial·Last updated May 29, 2026·7 min read
Does microdosing work? Honestly, the answer is "it depends what you mean by work" — and the best evidence is humbling. People who microdose psilocybin overwhelmingly report feeling better, but when researchers control for the placebo effect, most of that benefit appears to come from expectation rather than the substance itself. The signal is small, the science is young, and the question remains genuinely open.
This guide separates what people report from what controlled studies can actually show. We will walk through the most rigorous placebo-controlled trials, the large observational surveys, and the expectation research that ties them together — then give you an honest verdict you can actually use. For the wider picture, see our pillar guide to microdosing psilocybin and the live evidence tracker on our .
Before weighing the evidence, define the claim. "Microdosing works" usually bundles together three very different questions: does it produce a measurable acute effect on the day you take it, does it improve mood and wellbeing over weeks, and — critically — does any of that happen beyond what a placebo would produce? Each has a different answer.
That last distinction is everything. A treatment can make people genuinely feel better and still not "work" in the scientific sense, if an inert pill produces the same improvement. In a field driven by enthusiastic anecdote, the only honest test is a placebo-controlled comparison — and microdosing has now been put through several. The results are more sobering than the headlines suggest.
What do the placebo-controlled studies show?
The most rigorous studies — those that compare a real microdose against an identical-looking placebo — consistently find that the gap between the two is small or absent, while expectation explains a great deal. This is the single most important finding in the field, and it cuts against the popular narrative.
The landmark is the 2021 self-blinding citizen science study by Szigeti and colleagues, published in eLife — the largest placebo-controlled microdosing study to date. Participants assembled their own capsules so that neither they nor the researchers knew, on any given day, whether they were taking a microdose or an empty placebo. Both groups improved on psychological measures, but there were no significant differences between them. The authors concluded that the benefits "are not caused by the microdose, but rather by psychological expectations" — in short, that anecdotal benefits "can be explained by the placebo effect" (Szigeti et al., 2021, eLife; see also the Imperial College London write-up).
A second double-blind trial led by Cavanna in 2022, in Translational Psychiatry, gave 34 people 0.5 g of dried psilocybin mushrooms or placebo under laboratory conditions. Acute effects were significantly stronger on the active dose only for participants who correctly guessed what they had taken, and across most measures there was no benefit at all — with a few small shifts toward cognitive impairment. The authors concluded that "expectation underlies at least some of the anecdotal benefits" (Cavanna et al., 2022, Translational Psychiatry).
Why self-blinding matters
Microdosers are famously hard to blind: many believe they can "feel" a real dose, so they correctly guess their condition, and that guess shapes how they rate their own mood. Both Szigeti and Cavanna found exactly this — ratings tracked what people believed they had taken far more than what they actually took. That is the fingerprint of expectation, and it is why uncontrolled testimonials, however sincere, cannot settle the question.
But don't the big surveys say it helps?
Yes — and this is where the picture gets genuinely interesting. Large observational studies repeatedly find that people who microdose report better mood and mental health than those who don't. The catch is that observational data cannot separate the drug from the person, the ritual, the lifestyle, or the hope. Association is not causation.
The biggest of these come from Rootman and colleagues. Their 2022 Scientific Reports study followed 953 psilocybin microdosers against 180 non-microdosing controls and found greater observed improvements in mood and mental health at one month (Rootman et al., 2022). An earlier 2021 paper from the same group, with a large sample, reported that microdosers had lower levels of anxiety and depression and were often motivated by health reasons (Rootman et al., 2021, Scientific Reports).
These are real, carefully collected signals — but they are self-selected and unblinded. People who choose to microdose, buy the truffles, and track their mood are primed to notice improvement. That same expectation, which the placebo-controlled trials isolated as the main driver, is baked directly into survey data. The surveys tell us microdosers feel better; they cannot tell us the truffle is why.
How big is the expectation effect, really?
Large enough to explain most of what people experience. The 2019 PLOS ONE study by Polito and Stevenson tracked microdosers over time and found improvements in some domains alongside clear expectation effects — participants' beliefs about what microdosing would do shaped their reported outcomes (Polito & Stevenson, 2019, PLOS ONE). Taken together with Szigeti and Cavanna, a consistent pattern emerges.
Here is how the main lines of evidence stack up:
Study (year)
Design
Sample
Core finding
Szigeti et al. (2021), eLife
Placebo-controlled, self-blinding
~191 completed
No significant microdose-vs-placebo gap; benefits tracked expectation
Cavanna et al. (2022), Translational Psychiatry
Double-blind, lab
34
Acute effects only when condition was correctly guessed; minimal benefit overall
Rootman et al. (2022), Scientific Reports
Observational cohort
953 vs 180
Microdosers showed greater mood/mental-health improvement at one month
Rootman et al. (2021), Scientific Reports
Observational survey
Large
Lower self-reported anxiety and depression vs non-microdosers
Polito & Stevenson (2019), PLOS ONE
Longitudinal
~98
Some improvements, with clear expectation effects
The pattern is hard to miss: uncontrolled and observational studies look positive; the moment a credible placebo is introduced, the drug-specific effect mostly evaporates. That does not mean nothing is happening — it means most of what is happening is psychological, contextual, and real to the person, but not pharmacologically caused by the dose.
So what's the honest verdict?
The honest verdict is: the science is unsettled, the expectation effect is powerful, and any drug-specific benefit — if it exists — is currently small and unproven. That is not the same as "it does nothing." It means the dramatic claims you see online run far ahead of the evidence, and that nobody can yet promise you a reliable benefit from a microdose.
A few caveats keep the door open. Most rigorous trials are short (weeks, not months), use modest sample sizes, and study truffle or mushroom doses that vary in potency. Blinding is genuinely hard when people think they can feel the substance. It remains possible that a real but subtle effect exists for some people, some conditions, or some doses that current studies are not powered to detect. Researchers are actively working on this, and the field is moving.
What this means for you, practically:
Treat "microdosing cured my anxiety" claims with skepticism — the placebo-controlled data does not support strong promises.
The benefit you feel may be real to you yet not caused by the dose — expectation, routine, intention-setting, and lifestyle changes all matter.
Microdosing is not a substitute for treatment. If you are struggling, evidence-based care comes first — start with our screener and, in a crisis, our crisis resources.
Effects, even when felt, are not proof of safety or efficacy. Review the side effects and contraindications before considering anything.
If you want the full context — what microdosing is, how protocols differ, and where the law stands — work back through the microdosing psilocybin pillar. For the evidence as it evolves, we keep our research page and free courses current.
The takeaway is not cynical, just careful: people genuinely feel better, the science cannot yet credit the substance for it, and honest education means saying so plainly.
Frequently asked
Does microdosing actually work, or is it placebo?+
The largest placebo-controlled study (Szigeti et al., 2021) found no significant difference between a real microdose and a placebo — both groups improved. Researchers concluded that much of the benefit is explained by expectation, not the substance. A small drug-specific effect may exist but remains unproven.
If big surveys show benefits, why doubt them?+
Observational studies like Rootman et al. (2022) show microdosers report better mood, but they cannot separate the drug from the person, ritual, or hope. People who choose to microdose expect improvement, and that expectation — isolated in placebo trials — appears to drive most of the effect.
Could microdosing still help some people?+
Possibly. Current trials are short, modestly sized, and hard to blind, so a subtle real effect for some people or doses cannot be ruled out. But the evidence does not support strong claims, and microdosing is not a substitute for evidence-based mental-health care.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
